Table 11 Characteristics of recent clinical trials with liposomal amphotericin B in mono or combined therapy
From: Nanomedicine review: clinical developments in liposomal applications
References | Years | Phase | Disease | LF | n | Dose |
|---|---|---|---|---|---|---|
Cornely et al. (2017) | 2017 | III | IFD | AmBisome® | 228 | 5 mg/kg |
Romero et al. (2017) | 2017 | III | VL | AmBisome® | 109 | 3 mg/kg/day for 7 days |
AmBisome® + MA | 112 | 10 mg/kg single dose + 20 mg Sb+5/kg/day for 10 days | ||||
Rahman et al. (2017) | 2017 | III | VL | AmBisome® + Mil | 142 | 5 mg/kg + 17.5 mg/kg |
AmBisome + Par | 159 | 5 mg/kg + 150 mg/kg | ||||
AmBisome® | 158 | 15 mg/kg | ||||
Miyao et al. (2016) | 2016 | II | RFN | AmBisome® | 80 | 1 mg/kg |
Wasunna et al. (2016) | 2016 | II | VL | AmBisome® + SSG | 51 | 10 mg/kg + 20 mg/kg/day |
AmBisome® + Mil | 49 | 10 mg/kg + 2.5 mg/kg/day |